BiomX Inc.

BiomX Inc., listed on NYSE American under the ticker PHGE, is a clinical-stage biopharmaceutical company focused on developing proprietary phage-based therapies that target specific disease-associated bacteria. The company entered the public markets in October 2019 through its merger with Chardan NexTech Acquisition Corp., a blank-check vehicle sponsored by Chardan NexTech Sponsor LLC, an affiliate of Chardan Capital Markets. Operating in the biotechnology sector, BiomX has advanced pipeline programs addressing chronic and acute bacterial infections, including chronic rhinosinusitis. The company filed an 8-K disclosure with the SEC on August 11, 2026. Sign up on SpacDesk for full filing details, SPAC merger history, and real-time data on BiomX and hundreds of other post-merger companies.